LRP6 and hepatocellular carcinoma: Although this was not investigated, there is strong evidence that LRP6 can be cross-activated by several RTKs [61], suggesting the possibility that the changes observed in GBA-depleted hepatocellular carcinoma-derived cells may also be due in part by alterations in RTK activity.